TMO Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Thermo Fisher Scientific Inc (TMO) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and recent dividend increase make it an attractive option. While the pre-market price is slightly down, the long-term outlook remains solid, supported by favorable growth trends and analyst upgrades.
The MACD is positive and expanding, indicating bullish momentum. RSI is neutral at 47.186, suggesting no overbought or oversold conditions. Moving averages are converging, showing no clear trend, but the stock is trading near its pivot level of 510.936, with resistance at 523.68 and support at 498.192.
Analysts have consistently raised price targets, with multiple firms maintaining Buy or Outperform ratings.
The company reported strong Q4 2025 financials, with revenue and net income growing over 7% YoY and EPS increasing by 9%.
Dividend increase by 10% reflects confidence in cash flow and financial stability.
Healthcare sector is performing well as a defensive play amid broader market volatility.
Gross margin declined by 10.33% YoY in Q4 2025, which could be a concern for profitability.
The pre-market price is down by 0.56%, reflecting slight short-term weakness.
Broader market conditions (S&P 500 down 0.66%) may weigh on the stock in the near term.
In Q4 2025, Thermo Fisher reported revenue growth of 7.20% YoY to $12.215 billion, net income growth of 7.32% YoY to $1.964 billion, and EPS growth of 9.00% YoY to $5.21. However, gross margin declined by 10.33% YoY to 37.95%.
Analysts are overwhelmingly positive on TMO, with multiple firms raising price targets recently. The highest price target is $700, and the lowest is $615, indicating significant upside potential from the current price of $517.2. Analysts cite recovering end markets, increased pharma spending, and a strong 2026 outlook as key drivers.
